Prelude Therapeutics
PRLD Small CapHealthcare · Biotechnology
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prelude Therapeutics Stock at a Glance
Prelude Therapeutics (PRLD) is currently trading at $4.99 with a market capitalization of $397.4M. The 52-week range spans from $0.75 to $5.69; the current price is 12.3% below the yearly high.
💰 Dividend
Prelude Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
3 analysts rate Prelude Therapeutics (PRLD) on consensus: None. The average price target is $8.00, implying +60.32% from the current price. Analyst price targets range from $6.00 to $10.00.
Prelude Therapeutics: The Investment Case in Detail
Prelude Therapeutics (PRLD) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
With a gross margin near 100%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
What to Watch Next
- The analyst consensus price target implies 60.32% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 100% — indicates pricing power
- Solid balance sheet with low debt (D/E 29.45)
- –Negative free cash flow
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to relatively defensive market behavior, elevated short interest (7.13%).
Trading Data
Related Stocks in the Same Sector
Prelude Therapeutics at $4.48: micro-cap precision oncology with three shots on goal
The Real Story
Prelude Therapeutics is a clinical-stage biotech with three differentiated precision-oncology programs. The lead asset is a JAK2V617F inhibitor for myeloproliferative neoplasms (myelofibrosis, polycythemia vera, essential thrombocythemia) — a market dominated by Incyte's Jakafi but where the resistance/mutation patient subset is large and underserved. The second is a KAT6A inhibitor for advanced breast cancer (Pfizer is also in this space, validating the target). The third is a mutated-calreticulin degrader antibody conjugate — most original of the three.
The market is pricing PRLD at $356M cap with only $12M in revenue. EV/Sales 24x looks ridiculous, but that is the wrong frame for a clinical-stage biotech. The real metric is enterprise value relative to cash balance (~$130M net cash gives 2 to 3 years of runway at current burn) and trial readouts within that window.
What Smart Money Thinks
OrbiMed Advisors (oncology specialist HF) and Adage Capital (biotech-heavy HF) held positions through the 2024 lows. Insider buying from founder David Madden in late 2024 at $3.20 was the kind of signal that often precedes a Phase 1/2 readout. No mega-fund 13F whale beyond passive indexers.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
📉 The 3 Real Bear Points
Valuation in Context
Clinical-stage biotech does not value on traditional multiples. Risk-adjusted NPV of three programs: assume $500M peak sales for JAK2 mutant program at 40 percent commercial probability ($200M risk-adjusted), $1B peak for KAT6A at 30 percent probability ($300M), $300M for calreticulin at 20 percent ($60M). Sum: $560M risk-adjusted NPV. Subtract milestone payments and current cap of $356M is roughly fair.
🗓️ Next 3 Catalyst Dates
- :
- :
- :
💬 Daniel's Take
I avoid clinical-stage biotech as a category in personal accounts — the binary failure rate is uncomfortable. But for sophisticated readers building a biotech-basket exposure, PRLD is a reasonable name: three programs, strong cash, validated targets, smart-money holders. I would never own a single biotech as more than 0.5 percent. The right way to play this space is a basket of 15 to 20 small-cap biotechs with diverse programs; PRLD belongs in that basket, not as an individual conviction holding.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Prelude Therapeutics?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news